ACRO Biomedical Co., Ltd. (6748) - Total Liabilities
Based on the latest financial reports, ACRO Biomedical Co., Ltd. (6748) has total liabilities worth NT$26.08 Million TWD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ACRO Biomedical Co., Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how ACRO Biomedical Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ACRO Biomedical Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of ACRO Biomedical Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nekkar Asa
OL:NKR
|
Norway | Nkr447.24 Million |
|
Global Dividend Growth Split Corp Class A
TO:GDV
|
Canada | CA$167.00 Million |
|
Naturhouse Health SA
MC:NTH
|
Spain | €17.86 Million |
|
Eastern Water Resources Development and Management Public Company Limited
BK:EASTW
|
Thailand | ฿16.37 Billion |
|
Carmel Corp Ltd.
TA:CRML
|
Israel | ILA500.51 Million |
|
Shanghai Jinjiang International Travel Co Ltd
SHG:900929
|
China | $532.93 Million |
|
Venus Remedies Limited
NSE:VENUSREM
|
India | Rs1.74 Billion |
|
Votum SA
WAR:VOT
|
Poland | zł263.24 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down ACRO Biomedical Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 28.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ACRO Biomedical Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ACRO Biomedical Co., Ltd. (2019–2024)
The table below shows the annual total liabilities of ACRO Biomedical Co., Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$29.05 Million | -5.25% |
| 2023-12-31 | NT$30.66 Million | +53.90% |
| 2022-12-31 | NT$19.92 Million | -6.32% |
| 2021-12-31 | NT$21.27 Million | -14.99% |
| 2020-12-31 | NT$25.02 Million | +8.74% |
| 2019-12-31 | NT$23.01 Million | -- |
About ACRO Biomedical Co., Ltd.
ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials. The company offers products in the areas of wound care, orthopedics, dentistry, ophthalmology, cosmetic micro plastic surgery, beauty and eye care, and tissue engineering and regenerative medicines. The company was founded in 2014 and is based in Kaohsiung, Taiwan.